Behavioral Intervention
SURGE for Gastrointestinal Cancer
Dana Farber Cancer Institute, Boston, MA
Targeting 3 different conditionsSURGEN/ARecruitingLed by Nadine J McCleary, MD MPHResearch Sponsored by Nadine McCleary MD, MPHEligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Cancer type: Gastrointestinal, Hematologic, Thoracic
Advanced cancer: Metastatic disease OR Stage IV
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upup to 90 days of enrollment
Awards & highlights
No Placebo-Only Group
Study Summary
This trial will help researchers learn more about how best to support patients in their decision to undergo genomic testing as part of a clinical trial.
Eligible Conditions
- Gastrointestinal Cancer
- Lung Cancer
- Blood Cancers
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
You have cancer in your digestive tract, blood, or chest.
Select...
You have cancer that has spread to other parts of your body or is in stage IV.
Select...
The study is looking for people from certain groups who are often underrepresented in medical research. These groups include Black, Latinx, American Indian, Pacific Islander, those with limited English proficiency in Spanish, those over 70 years old, and those with low income or social determinants of health needs. If you indicate on the New Patient Intake Questionnaire that you have a social determinant of health need, you may also qualify.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 90 days of enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 90 days of enrollment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Genomic testing uptake
Secondary outcome measures
Acceptability of questionnaire modality
Patient interaction with the intervention
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Arm C (informational video and patient navigation)Experimental Treatment1 Intervention
Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to the SURGE intervention where they will receive:
Informational Video and Patient Navigation
Group II: Arm B (informational video)Experimental Treatment1 Intervention
Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to the SURGE intervention where they will receive:
Informational Video
Group III: Arm A (standard of care)Active Control1 Intervention
Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to Standard of Care (SOC) and receive:
Standard of Care
Find a site
Who is running the clinical trial?
Nadine McCleary MD, MPHLead Sponsor
Nadine McCleary, MD, MPHLead Sponsor
Bristol-Myers SquibbIndustry Sponsor
2,562 Previous Clinical Trials
4,029,836 Total Patients Enrolled
Nadine J McCleary, MD MPHPrincipal Investigator
Dana-Farber Cancer InstituteMedia Library
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the main goals of this clinical research endeavor?
"According to Bristol-Myers Squibb, the primary metric for assessment will be PROFILE genomic testing completion rates over a 3 year time frame. Additionally, this study is observing secondary objectives which include determining consent rate of patients with insufficient tissue samples and no archival specimens available as well as exploring correlations between patient demographics and disease characteristics with clinical trial awareness/readiness."
Answered by AI
Are there any available openings for prospective participants in this clinical trial?
"According to clinicaltrials.gov, this medical trial is not presently recruiting patients - the original posting was on November 1st 2022 and it was last updated on May 11th 2022. Although no longer seeking participants right now, there are a great deal of other research studies that are currently open for enrolment (1882)."
Answered by AI